obesity
Conditions
Interventions
treatment group (Endoscopic sleeve gastroplasty):none
control group:none
Sponsors
Beijing Friendship Hospital ,Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Age range of 18-60 years old (including 18 and 60 years old), male or female not limited; 2. 30kg/m^2 <= BMI <40kg/m^2; 3. The ASA classification is grade I - II; 4. Patients understand the purpose of the trial, voluntarily participate in the trial, and sign informed consent; 5. The patient agreed to undergo follow-up evaluation, laboratory examination, and dietary intervention as required by the protocol;
Exclusion criteria
Exclusion criteria: 1.History of upper gastrointestinal surgery (except cholecystectomy); 2.Have undergone open or laparoscopic bariatric surgery; 3.Active peptic ulcer; 4.Patients with bleeding or potential bleeding conditions in the digestive tract, such as esophageal or fundus varicose veins, intestinal telangiectasia, etc; 5.Accompanied by advanced malignant tumors of digestive tract or other organs; 6.Diagnosed with type 1 diabetes; 7.Islet beta cell function has been basically lost, C-peptide = 1/2 of the normal low limit or the C-peptide release curve under glucose load is low; 8.Has a difficult mental illness to control; 9.Current drug or alcohol abuse problems; 10.According to the researchers' judgment, patients with poor systemic condition and contraindication of endoscopy exist; 11.Patients with coagulation function deemed unsuitable for endoscopic surgery; 12.Patients with severe hepatic and renal dysfunction with a creatinine concentration greater than 180µmol/L; 13.Patients with severe infection that is not under control and is not suitable for surgery; 14.Pregnant and lactating women; 15.Women who have planned a pregnancy within the last 1 year; 16.Inability or unwillingness to use proton pump inhibitors; 17.Patients who require regular use of non-steroidal anti-inflammatory drugs, including aspirin, diclofenac, ibuprofen, naproxen, or other known stomach irritants; 18.Untreated or uncontrolled thyroid dysfunction; 19.Patients who had taken corticosteroids, immunosuppressants, anesthetics, and weight loss drugs in the 28 days prior to surgery; 20.NYHA patients with cardiac function grade III or above or pulmonary dysfunction; 21.Patients with a narrow pharynx or esophagus that cannot be passed through an endoscope; 22.Participants who have participated in any clinical trial and received investigational drug or device therapy within 3 months prior to screening; 23.Allergic to polypropylene, titanium alloy and other materials; 24.Eating disorders, including anorexia or binge eating; 25.Patients who are prepared to undergo surgical weight loss surgery of their choice within the next year; 26.Patients with any other condition that the investigator deems inappropriate to participate in this trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| feeding hormones; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intestinal flora lineage; | — |
Countries
China
Contacts
Public ContactWei Yongqiu
Beijing Friendship Hospital ,Capital Medical University
Outcome results
None listed